New drug combo aims to extend life in aggressive lung cancer
Disease control
Recruiting now
This phase 2 trial tests whether adding two drugs (durvalumab and ceralasertib) after standard chemo-immunotherapy can help control extensive-stage small cell lung cancer. About 30 people who have not had prior treatment will receive the combination. The main goal is to see how l…
Phase: PHASE2 • Sponsor: Muhammad Furqan • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC